SOX1 is a transcriptional activator functioning as a developmental switch in neural differentiation. It maintains neural stem cell identity by suppressing neuronal differentiation through counteraction of proneural proteins 1. SOX1 expression decreases during neural pathway differentiation, with NGF-β overexpression promoting this transition from SOX1+ stem cells to differentiated neural cells 1. In cancer biology, SOX1 plays dual roles. It promotes glioma stem cell proliferation, invasion, and migration due to elevated expression in glioblastoma cells 2. Additionally, SOX1 marks stem-like cell clusters across small cell lung cancer subtypes, appearing in ASCL1+SOX1+ populations 3. Clinically, SOX1 methylation serves as a diagnostic biomarker for cervical neoplasia. SOX1 methylation levels correlate positively with cervical intraepithelial neoplasia severity, with diagnostic odds ratio of 68.95 for cervical cancer detection (AUC 0.92) 4. As part of a PAX1/SOX1 methylation panel, it achieves 77.16% sensitivity and 91.67% specificity for CIN2+ detection, improving triage efficiency for HPV-positive women 5. Disease associations include paraneoplastic brainstem encephalitis, where SOX1 antibodies occur in cancer patients 6, and fibromyalgia syndrome, where anti-SOX1 antibodies correlate with immune activation 7.